Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators
Just weeks before Shionogi is scheduled to hear back from the FDA on treating complicated urinary tract infections with its antibiotic, the Japanese pharma has another slate of positive data on a different indication to share.
Investigators laid out the full numbers on cefiderocol in adults with nosocomial pneumonia caused by gram-negative pathogens — a particularly tough to beat condition for hospitalized patients, given its multiple resistance mechanisms. In a Phase III, the drug appeared non-inferior to high-dose meropenem in all-cause mortality after two weeks of treatment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.